BIVI Offering

BioVie Inc. Announces Pricing of $12 Million Public Offering

Published August 08, 2025 at 12:43 AM

CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”) (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant (the “Pre-Funded Warrants”) and one Warrant). Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public at the public offering price of each unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). The gross proceeds to the Company from this offering are expected to be approximately $12 million, before deducting underwriting discounts an

Related Questions

How will the $12 million gross proceeds be allocated—e.g., R&D, clinical trials, or debt repayment—and what milestones does the company aim to fund? How will the $2.00 per unit pricing compare to BioVie's recent trading price and affect immediate market perception? What is the expected dilution impact on existing shareholders from the issuance of 6,000,000 new units and warrants? Is there a lock‑up or resale restriction period for the newly issued shares and warrants that could affect short‑term supply dynamics? Will the increased float improve liquidity and bid‑ask spreads for BIVI, or could it lead to heightened volatility? What is the size of the underwriting discount and overall offering expenses, and how do they impact net proceeds to the company? What is the anticipated impact of this capital raise on BioVie's cash runway and timeline to key clinical trial milestones? Are there any covenants or redemption rights associated with the pre‑funded warrants that could affect future capital structure? How does this public offering size and pricing compare to recent capital raises by peer biotech companies in the liver‑disease and neuro‑degenerative space? What are the specific terms of the warrants (exercise price, expiration date, and any reset or anti‑dilution features) and how might they influence future equity upside?